GALANTAMINE HYDROBROMIDE - Generic Drug Details

What are the generic sources for galantamine hydrobromide and what is the scope of patent protection?

Galantamine hydrobromide is the generic ingredient in three branded drugs marketed by Aurobindo Pharma, Barr, Impax Labs, Pharmobedient, Sun Pharm, Watson Labs, Janssen Pharms, Hikma, Apotex Inc, Aurobindo Pharma Ltd, Chartwell Rx, Heritage Pharma, Mylan, Sandoz, Senores Pharms, Yabao Pharm, and Zydus Pharms Usa Inc, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for galantamine hydrobromide. Nine suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for GALANTAMINE HYDROBROMIDE

US Patents:	0
Tradenames:	3
Applicants:	17
NDAs:	22
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	9
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	22
Patent Applications:	1,512
Drug Prices:	Drug price trends for GALANTAMINE HYDROBROMIDE
What excipients (inactive ingredients) are in GALANTAMINE HYDROBROMIDE?	GALANTAMINE HYDROBROMIDE excipients list
DailyMed Link:	GALANTAMINE HYDROBROMIDE at DailyMed

See drug prices for GALANTAMINE HYDROBROMIDE

Recent Clinical Trials for GALANTAMINE HYDROBROMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 1
Duke University	Phase 4
Ortho-McNeil Neurologics, Inc.	Phase 4

See all GALANTAMINE HYDROBROMIDE clinical trials

Generic filers with tentative approvals for GALANTAMINE HYDROBROMIDE

Applicant	Application No.	Strength	Dosage Form
		12MG	TABLET; ORAL
		8MG	TABLET; ORAL
		4MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for GALANTAMINE HYDROBROMIDE

Drug Class	Cholinesterase Inhibitor
Mechanism of Action	Cholinesterase Inhibitors

Medical Subject Heading (MeSH) Categories for GALANTAMINE HYDROBROMIDE

Cholinesterase Inhibitors

Nootropic Agents

Parasympathomimetics

Anatomical Therapeutic Chemical (ATC) Classes for GALANTAMINE HYDROBROMIDE

N06DA	Anticholinesterases
N06D	ANTI-DEMENTIA DRUGS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for GALANTAMINE HYDROBROMIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	16 mg and 24 mg	021615	1	2006-03-11
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	8 mg	021615	1	2006-03-02
RAZADYNE	Tablets	galantamine hydrobromide	4 mg, 8 mg and 12 mg	021169	14	2005-02-28

US Patents and Regulatory Information for GALANTAMINE HYDROBROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	TABLET;ORAL	077603-001	Aug 28, 2008		DISCN	No	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005		DISCN	Yes	No
Zydus Pharms Usa Inc	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	TABLET;ORAL	078898-002	Feb 17, 2011	AB	RX	No	No
Sandoz	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	TABLET;ORAL	077589-001	Jun 22, 2009	AB	RX	No	No

Expired US Patents for GALANTAMINE HYDROBROMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-003	Feb 28, 2001	6,358,527
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-002	Feb 28, 2001	6,099,863
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005	4,663,318
Janssen Pharms	RAZADYNE	galantamine hydrobromide	TABLET;ORAL	021169-001	Feb 28, 2001	6,358,527

GALANTAMINE HYDROBROMIDE Market Analysis and Financial Projection

Last updated: February 12, 2026

What Is the Market Size and Growth Potential for Galantamine Hydrobromide?

Galantamine Hydrobromide is primarily used for mild to moderate Alzheimer’s disease. The global Alzheimer’s drug market, valued at approximately $4.4 billion in 2022, is expected to grow at a compounded annual growth rate (CAGR) of 3-5% until 2030, reaching nearly $6 billion. Galantamine's market share within this space is estimated at 10-15%.

In 2022, the global sales of galantamine drugs, including formulations from brands such as Razadyne (Johnson & Johnson) and reformulations by generics, ranged between $110 million and $200 million.

Market Drivers

• Rising prevalence of Alzheimer’s: Estimated to affect 55 million globally in 2020, expected to rise to 78 million by 2030 (WHO).
• Aging populations in North America, Europe, and parts of Asia.
• Increasing off-label use for cognitive enhancement in specific populations.

Market Constraints

• Competition from other cholinesterase inhibitors like donepezil and rivastigmine.
• Limited efficacy: Galantamine shows modest symptomatic benefits with no proven disease-modifying effects.
• Regulatory hurdles and patent expirations: Generics entered the market around 2012, reducing branded sales.

How Do Regulatory and Patent Factors Influence Commercialization and Revenue?

Current Patent Landscape

• Original patents for Razadyne expired in 2012.
• Some newer formulations or combinations might be under secondary patents until 2025-2027.
• Generics dominate the market, accounting for over 80% of sales.

Regulatory Environment

• FDA approval for new indications or formulations is challenging due to the limited efficacy profile.
• European Medicines Agency (EMA) approvals mirror US standards, affecting international market access.

Impact on Revenue

• Branded sales have declined sharply post-generic entry.
• Companies holding secondary patents or new formulations (e.g., extended-release tabs) can prolong revenue streams through exclusivity until patents expire.

What Are the Recent R&D Trends and Pipeline Developments?

• Focus on combination therapies integrating galantamine with memantine.
• Research into delivering galantamine via novel routes such as transdermal patches or sustained-release devices.
• Clinical trials exploring off-label uses for other cognitive disorders, but with limited success to date.

Limited late-stage pipeline products exist. Most R&D efforts aim to improve delivery modes or combine galantamine with other agents to enhance efficacy.

What Is the Financial Trajectory for Parkinson’s Disease and Alzheimer’s Drug Markets and Galantamine’s Role?

Revenue Trends

• Post-2012, branded sales declined sharply, with current estimates at $110M–$200M globally.
• The bulk of revenues now derive from generics and off-patent formulations.

Investment in R&D

• Companies allocate minimal R&D budgets for galantamine derivatives due to limited efficacy and market saturation.
• Focus has shifted to novel disease-modifying agents, rather than symptomatic treatments like galantamine.

Market Outlook

• Limited growth prospects barring breakthroughs in efficacy or new delivery methods.
• The strategic value of galantamine as a combination agent remains uncertain, with no major recent approvals or pipeline milestones.

What Are the Future Opportunities and Risks?

Opportunities

• Developing improved formulations that enhance bioavailability.
• Combining galantamine with other neuroprotective agents.
• Expanding to off-label uses, including cognitive decline in other neurodegenerative conditions.

Risks

• Arrival of new disease-modifying drugs diminishing the role of symptomatic treatments.
• Patent expirations leading to market erosion.
• Clinical efficacy limitations reducing attractiveness to investors.

Key Takeaways

• Market size for galantamine hydrobromide is declining due to generic competition.
• Revenue relies heavily on aging populations and off-label uses.
• R&D efforts are limited; the pipeline is sparse.
• Competitive landscape is dominated by other cholinesterase inhibitors with similar efficacy profiles.
• Future growth hinges on improving formulations, combination strategies, or new indications.

FAQs

What is the primary use of galantamine hydrobromide?

Treating mild to moderate Alzheimer’s disease by increasing acetylcholine levels.

How significant is generic competition for galantamine?

It accounts for over 80% of sales since patent expirations in 2012, drastically reducing branded revenues.

Are there ongoing developments in galantamine formulations?

Yes, research focuses on sustained-release, transdermal patches, and combination therapies, but with limited commercial impact so far.

What is the potential impact of new Alzheimer’s treatments on galantamine’s market?

Emergence of disease-modifying agents like aducanumab and lecanemab could phase out symptomatic agents, including galantamine.

What are the main challenges in expanding galantamine’s market?

Limited efficacy, generic competition, regulatory hurdles, and competing therapies with higher perceived benefits.

---

Sources:

1. World Health Organization (WHO). "Dementia." 2020.
2. MarketWatch. “Alzheimer’s Drug Market 2022-2030.” 2022.
3. US Food and Drug Administration (FDA). "Razadyne Label." 2012.
4. IQVIA. “Global Pharmaceutical Sales Data.” 2022.